0001078782-13-001023.txt : 20130520 0001078782-13-001023.hdr.sgml : 20130520 20130520131330 ACCESSION NUMBER: 0001078782-13-001023 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130520 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20130520 DATE AS OF CHANGE: 20130520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30402 FILM NUMBER: 13857600 BUSINESS ADDRESS: STREET 1: 150 ORCHARD ROAD CITY: ORCHARD PLAZA 08-02 STATE: U0 ZIP: 238841 BUSINESS PHONE: 000-000-0000 MAIL ADDRESS: STREET 1: 150 ORCHARD ROAD CITY: ORCHARD PLAZA 08-02 STATE: U0 ZIP: 238841 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 8-K 1 f8k052013_8k.htm CURRENT REPORT ON FORM 8-K Current Report on Form 8-K

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 20, 2013 (May 15, 2013)


VolitionRX Limited

 (Exact name of registrant as specified in its charter)

 

 

 

 

Delaware

000-30402

91-1949078

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

 

Identification Number)

 


1 Scotts Road

#24-05 Shaw Centre

Singapore 228208

 

 

(Address of principal executive offices)

 

 

(201) 618-1750

 

 

(Registrant’s Telephone Number)

 



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

      .    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 


      .    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 


      .    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


      .    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 





VOLITIONRX LIMITED

Form 8-K

Current Report


ITEM 5.02.

DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS


Effective May 15, 2013, Satu Vainikka (“Dr. Vainikka”) resigned from all positions with the Company including, but not limited to, that of Director.  Dr. Vainikka’s resignation did not involve any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise.


On May 16, 2013, the Company’s Board of Directors accepted Dr. Vainikka’s resignation.

  

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  

  

  

  

  

VOLITIONRX LIMITED

  

Date: May 20, 2013

By:  

/s/ Cameron Reynolds

 

  

  

Cameron Reynolds

  

  

Chief Executive Officer & President